CNS PHARMACEUTICALS INC
CNSPNASDAQTrading Snapshot
- Day Range
- $4.87 – $4.97
- 52-Week Range
- $1.90 – $10.59
- Volume
- $1.80B
- Avg Volume
- $2.11B
- Shares Outstanding
- 1.5M
- Next Earnings
- Oct 27, 2026
Fundamentals Snapshot
- Annual Revenue
- $746,319
- Last Q Revenue
- $201,953
- P/E Ratio
- —
- P/S Ratio
- —
- EPS (TTM)
- $-23.14
- Dividend Yield
- —
- Dilution (1yr)
- +276.4%
Why Investors Own CNSP
- ✓High-growth profile — revenue up -9.7% YoY with expanding US Equity exposure.
- ✓Healthy economics — 53% gross margin and 28% free-cash-flow margin.
- ✓New products and segments could unlock additional revenue streams.
Execution delays, intensifying competition, and valuation compression if growth decelerates.
CNS PHARMACEUTICALS INC
CNSP
StockOtter · stockotter.spaceAbout CNS PHARMACEUTICALS INC
CNS Pharmaceuticals, Inc. is a clinical-stage pharmaceutical firm primarily focused on developing innovative anti-cancer therapies for tumors affecting the brain and central nervous system. Its primary investigational compound, Berubicin, an anthracycline, is currently progressing through Phase I and II clinical trials as a potential treatment for glioblastoma multiforme, an aggressive form of brain cancer. To bolster its research and development initiatives, the company has entered into several strategic agreements. These include licensing arrangements with Houston Pharmaceuticals, Inc., The University of Texas M.D. Anderson Cancer Center, and Animal Life Sciences, LLC. Additionally, CNS Pharmaceuticals has a development agreement in place with WPD Pharmaceuticals Inc. and a collaborative partnership with Reata Pharmaceuticals, Inc. The company was founded in 2017 and is headquartered in Houston, Texas.
Otter Score Breakdown
How it's scoredFive components, each rated 1–5★ and equally weighted (20%), averaged to a 0–100 score:💎 Quality — gross margin🚀 Growth — revenue YoY⚖️ Valuation — P/S ratio⚡ Momentum — 30-day price change💧 Dilution — 1-yr share issuance (buybacks score higher)Analyst Price Target
ⓘLatest News & Updates
CNS Pharmaceuticals Details Business Development Strategy Driving Its Next Phase of Growth
Chief Business Officer, Dylan Wenke, Participates in Virtual Investor "What This Means" Segment Access the segment here HOUSTON, TX / ACCESS Newswire / September 1, 2026 / CNS Pharmaceuticals, Inc. (NASDAQ:CNSP) ("CNS" o
CNS Pharmaceuticals Participates in the Virtual Investor "Why Now" On-Demand Conference
Video webcast now available here HOUSTON, TX / ACCESS Newswire / August 27, 2026 / CNS Pharmaceuticals, Inc. (NASDAQ:CNSP) ("CNS" or the "Company"), a biotechnology company focused on building a pipeline of innovative th
CNS Pharmaceuticals Reports Second Quarter 2026 Results, Highlighting Strengthened Balance Sheet and Accelerated Execution of Strategic Transformation
Company reports approximately $20.0 million cash position and extended operating runway following oversubscribed $22.5 million financing, as it advances its pivot toward a diversified, high-value pipeline HOUSTON, TX / A